The Best Validation Software for Biotech Companies in 2026
Biotech validation software, the 2026 ranking. Short answer: Matrix Validate is the best validation software for biotech companies in 2026, followed by Kneat Gx, Veeva Validation Management, ValGenesis, GoVal, Res_Q by Sware, Valkit.ai and MasterControl VxT. Matrix Validate is first because a growing biotech's validation problem is computer systems arriving faster than the CSV team grows, and it keeps every requirement, risk and test as connected data, scales testing to risk under GAMP 5 and ICH Q9(R1), and shows exactly what to retest when a SaaS vendor ships a release.
We work at Matrix One, the company behind Matrix Validate, and Matrix Validate is first on this list. We say that up front so you can weigh the ranking accordingly. Every competitor fact below comes from that vendor's own website, read on 9 November 2026, or from our alternatives pages, which were checked against vendor sites on 3 November 2026.
Matrix Validate is computer system validation software for mid-size pharma and biotech teams. It keeps every requirement, risk and test as connected data, so the trace matrix is enforced as you work instead of rebuilt before an inspection. This list is written for biotech companies moving from clinical work toward commercial supply, with a growing stack of configured and SaaS systems and a first GMP inspection on the horizon.
What does validation software for a biotech company actually have to do?
It has to let a small team validate a fast-growing portfolio of systems to a standard an inspector accepts. In a typical growing biotech the systems arrive in a rush: an eQMS, a LIMS, an ELN, an ERP, a document system, bioprocess and lab software, and tools built in-house. Most are configured or custom, GAMP 5 categories 4 and 5, and many are SaaS products that change several times a year.
EU GMP Annex 11 (2011) sets the frame. Its principle says the application should be validated and IT infrastructure qualified. Clause 1 says decisions on the extent of validation should rest on a justified and documented risk assessment. Clause 3.3 says documentation supplied with commercial off-the-shelf products should be reviewed by regulated users to check that user requirements are fulfilled. Clause 4.4 says user requirements should be traceable throughout the life cycle.
Read together, those clauses give a biotech four jobs: own your requirements even when a vendor supplies them; test to risk, because a small team cannot test everything to the same depth; keep up with vendor releases without starting again; and produce signed, inspection-ready documents on request. The tools below are ranked on how well they do those four jobs for a team that is growing, not for one that is already global.
8 best validation software for biotech companies shortlist
| Tool | Best for |
|---|---|
| Matrix Validate | Mid-size biotech and pharma CSV teams validating configured and SaaS systems with an enforced trace matrix |
| Kneat Gx | Biotechs scaling toward global, multi-site digital validation across many validation types |
| Veeva Validation Management | Biotechs already running Veeva Vault QualityDocs and QMS |
| ValGenesis | Larger biotechs that want validation and process lifecycle work on one AI-native platform |
| GoVal | Biologics and cell and gene therapy teams replacing paper protocols |
| Res_Q by Sware | Life sciences IT teams managing continuous SaaS updates with AI assistance |
| Valkit.ai | GxP teams running CQV, CSV and CSA together with human-in-the-loop AI |
| MasterControl VxT | Biotechs that run MasterControl and need it validated through upgrades |
Which tool fits which kind of biotech, at a glance?
| Tool | Built for | Strongest on |
|---|---|---|
| Matrix Validate | CSV teams at companies of typically 100 to 3,000 people | Requirements as data, risk-scaled testing, impact analysis at each release |
| Kneat Gx | Biotech, pharma, device and consumer health companies | Breadth of validation types and scale across sites |
| Veeva Validation Management | Veeva Vault quality customers | One audit trail across validation, QualityDocs and QMS |
| ValGenesis | Large life sciences enterprises | Validation plus cleaning and process lifecycle suites |
| GoVal | Biologics and ATMP teams | Configurable ATMP templates and GAMP 5 classification |
| Res_Q by Sware | IT teams validating changing software | Automated impact assessment across parallel changes |
| Valkit.ai | GxP validation, assurance and C&Q teams | AI proposals that a subject matter expert accepts or dismisses |
| MasterControl VxT | MasterControl customers | Risk-based validation of MasterControl upgrades |
Read the table as a map of fit, not a scorecard. The column that matters most for a growing biotech is the last one: where the tool puts its effort. Several tools here are built to cover process, cleaning and facility validation for large manufacturers. If your next milestone is validating a handful of SaaS systems before commercial supply, depth on CSV matters more than breadth across validation types.
When does a biotech's validation obligation actually start?
Earlier than many teams expect, and not all at once. Under 21 CFR 210.2(c), the production of an investigational drug for a phase 1 study is exempt from compliance with Part 211, but that exemption ends once the drug is made available for a phase 2 or phase 3 study or is lawfully marketed. From that point, 21 CFR 211.68(b) applies to the computer systems involved.
| Clause | What it requires |
|---|---|
| 21 CFR 210.2(a) | Parts 210 and 211 supplement the biologics regulations in parts 600 to 680 and Part 1271 for HCT/Ps regulated as drugs |
| 21 CFR 210.2(c) | Phase 1 investigational drug production is exempt from Part 211 until the drug is used in phase 2 or 3 or marketed |
| 21 CFR 211.68(b) | Appropriate controls over computer systems so record changes are made only by authorised personnel |
| 21 CFR 11.10(a) | Validation of systems to ensure accuracy, reliability, consistent intended performance and detection of altered records |
| Annex 11 clause 3.3 | Regulated users review documentation supplied with off-the-shelf products against user requirements |
| Annex 11 clause 4.3 | An up to date inventory of relevant systems and their GMP functionality |
| Annex 11 clause 4.4 | User requirements based on risk and GMP impact, traceable throughout the life cycle |
| Annex 11 clause 11 | Periodic evaluation to confirm systems remain in a valid state |
The practical point is timing. A biotech that waits for phase 3 to start CSV ends up validating a dozen live systems at once, under deadline, with requirements written after the fact. A team that starts with the inventory Annex 11 clause 4.3 asks for, and adds systems to it as they arrive, validates in a steady rhythm instead.
21 CFR 11.10(a) also applies to the validation tool itself if it holds GxP records, which is why the vendor's own validation package matters. We cover that under the demo checks below.
How did we rank them?
| Item | What it means |
|---|---|
| Fit for a growing CSV team | Can a team of a few people run it without an enterprise rollout? |
| Requirements as data | Are URS, FS and DS items you can approve, change and reuse, or text in a document? |
| Risk drives test scope | Does a risk score set how deep each test goes, in line with GAMP 5 and ICH Q9(R1)? |
| Release handling | When a SaaS vendor ships a release, does the tool show what to retest? |
| Inspection output | Are plans, trace matrices and reports generated, signed and exportable? |
| Published evidence | Does the vendor's own site say it serves biotech, and what does it claim? |
We weighted the first two most heavily. A growing biotech hires validation people slowly and adds systems quickly, so a tool that needs a dedicated administrator or a long implementation solves the wrong problem. The ranking reflects fit for mid-size biotech and pharma CSV teams. A global manufacturer validating processes, cleaning and facilities would order the list differently, and the large platforms would rise.
Which 8 tools made the list, and in what order?
1. Matrix Validate
Matrix Validate is computer system validation software made by Matrix One for mid-size pharma, biotech and combination product companies, typically 100 to 3,000 people. It is built for CSV teams validating configured or custom GxP systems, GAMP 5 categories 4 and 5: eQMS, LIMS, ERP, document management, lab software, cloud and SaaS applications, and tools built in-house.
URS, FS and DS are individual items with their own ID, fields, version history and approval, so a biotech can take the requirements a SaaS vendor supplies, review and approve them for its own configuration, and reuse them across systems. A built-in risk assessment in line with GAMP 5 and ICH Q9(R1) scores each requirement for patient safety, product quality and data integrity impact, and scales testing to the risk. Trace rules flag any requirement without a test and any risk without a control.
Testers run scripts step by step, with pass or fail, comments, screenshots and attachments recorded against each step as they test, and deviations are raised against the exact step. The validation plan, trace matrix and validation summary report are generated from live data, signed with 21 CFR Part 11 compliant e-signatures that ask for full credentials at the point of signing, and exported as PDFs to your QMS.
Release handling is what puts it first for a biotech. Copy the validated project, apply the vendor's release notes, and impact analysis flags every item downstream; redlining shows what changed and what needs retesting. It runs as SaaS or on-premise, with Jira, Azure DevOps and GitLab integrations and a REST API. Matrix One builds for life sciences only, has been in the market since 2014, and more than 500 life sciences companies worldwide use its products, according to matrixone.health as of November 2026.
2. Kneat Gx
Built for life sciences companies that want digital validation at global scale. Kneat says on kneat.com that it is built for biotechnology, pharmaceuticals, medical devices and consumer health, and that 9 of the world's top 10 life sciences companies trust Kneat. Its biotechnology page talks about complexity across process, analytical method, equipment, cleaning, computer system, assay, sterilization and facility validations.
Our Kneat alternative page, checked against kneat.com on 3 November 2026, records coverage for computer systems, equipment, process, cleaning, utilities and facilities, plus a dedicated implementation team. For a biotech planning several manufacturing sites and many validation types, that breadth is the reason to shortlist it.
3. Veeva Validation Management
Built for biotechs that already run Veeva Vault QualityDocs and Vault QMS. Veeva says Validation Management streamlines commissioning, qualification and validation across computerized systems, facilities, utilities, equipment and processes, that it is unified with QualityDocs and QMS, and that it captures all user actions, tasks and signatures in a single audit trail.
Veeva's site also has a section for emerging biotechs and points those organisations to Veeva Basics. If your quality documents and events already live in Vault, keeping validation in the same suite is a strong argument. Our Veeva Validation Management alternative page has the side by side.
4. ValGenesis
Built for large life sciences enterprises that want validation and process lifecycle work on one platform. ValGenesis says on valgenesis.com that 30 of the top 50 life sciences companies use its Smart GxP platform, and it describes itself as AI-native. On its computer system validation page it says its suite captures step-level evidence and ALCOA+ audit trails automatically, meeting 21 CFR Part 11 and Annex 11 requirements.
Its products include iVal for validation and iClean for cleaning validation, as recorded on our ValGenesis alternative page. A biotech that expects cleaning and process validation to dominate its validation workload as it scales up manufacturing is the natural buyer.
5. GoVal
Built for biotech and biologics teams replacing paper protocols, at govalidation.com. GoVal's biotech page describes a purpose-built validation lifecycle management system covering LIMS, ELN, bioreactor control software and ATMP manufacturing systems, aligned with GAMP 5, 21 CFR Part 11, EU Annex 11 and ICH Q10.
GoVal says it offers configurable templates for ATMP manufacturing processes, including cell culture, viral vector and gene editing platforms, and a risk engine that applies GAMP 5 categories 1 to 5 to each system. For a cell and gene therapy company that wants templates for novel manufacturing systems, that focus is its distinguishing strength.
6. Res_Q by Sware
Built for life sciences IT teams that validate software which changes continuously. Sware says on sware.com that Res_Q builds a risk-based approach into the lifecycle with agentic validation that meets GAMP 5 requirements, and that it manages multiple parallel changes in GxP and non-GxP systems through automated impact assessment.
Sware publishes a case study in which, by its own account, a growing biotech reduced validation time by 40 percent while managing multiple sites. Sware still sells Res_Q under its own name; it is a different product from Tricentis Vera.
7. Valkit.ai
Built for GxP teams running validation, assurance and C&Q in one place. Valkit.ai describes itself as Gen 2 digital validation for life sciences, with human-in-the-loop AI: you paste a change, review AI proposals, and subject matter experts accept or dismiss them, never auto-applied. It imports requirements and tickets from Jira and Azure DevOps.
Its home page links an announcement that a global cell and gene therapy CDMO selected Valkit.ai, and lists IQ, OQ and PQ execution with evidence capture. Our Valkit alternative page has more detail.
8. MasterControl Validation Excellence Tool (VxT)
Built for biotechs that run MasterControl and need it validated through each upgrade. MasterControl says its patented VxT assesses risks, offers testing recommendations and helps you focus on critical processes, and that a subscription bundle, annual or quarterly, uses the VxT change control process to maintain your validated state.
MasterControl's site lists solutions for cell and gene therapies and for blood, biologics and tissue. VxT is positioned for validating MasterControl's own software rather than your other GxP systems, so a MasterControl customer would typically pair it with a tool for the rest of the portfolio.
For completeness: Validfor describes itself as an AI-native validation platform and its FAQ names pharmaceutical, biotechnology and medical device companies as the organisations it suits. It is worth a look for teams that want AI agents in the validation workflow; we left it off the eight because it does not publish a biotech-specific offering.
What Matrix Validate is built for, and what you would buy alongside it
Matrix Validate is built for CSV teams at mid-size biotech, pharma and combination product companies that validate configured, custom and SaaS GxP systems and want the trace matrix enforced as they work. Teams that build their own GxP applications get Jira, Azure DevOps and GitLab integrations, and teams with strict data policies can run it on-premise.
It focuses on computer system validation and in-house equipment qualification: URS, DQ, IQ, OQ and PQ for in-house equipment, test rigs and lab instruments. Process validation, cleaning validation, analytical method validation and large commissioning and qualification programmes with shop-floor paperless execution are outside its current focus.
That is where the large platforms are strong. ValGenesis covers cleaning validation in iClean, and Kneat Gx covers process, cleaning and facilities across global sites. A biotech scaling up its own manufacturing could use one of them for the plant and Matrix Validate for CSV. GoVal's ATMP templates are a genuine strength for cell and gene therapy manufacturing systems, and Matrix Validate does not ship ATMP-specific templates.
What do you need in place before Matrix Validate works?
A validation tool reflects the process you give it. Four things make the first year go well:
IT and Quality owning it together, with the split written down: IT for the systems, Quality for the approvals.
A system inventory with GAMP 5 categories, which Annex 11 clause 4.3 expects anyway.
Named preparers and approvers for each system, so signatures route to the right people from day one.
A scope decision: for now, computer system validation, CSA and simple in-house equipment qualification.
A typical starting point we see is a US biotech, two years commercial, with about 20 GxP systems validated in Word and Excel. A sensible first project is the system with the next vendor release due, because that is where rebuilding a trace matrix by hand costs most.
Who should own validation in a growing biotech?
The system owner, usually in IT or the business, owns the system and its changes. Quality owns the approval of the validated state. The CSV lead owns the method. Annex 11 clause 2 asks for close cooperation between process owners, system owners, qualified persons and IT, with defined responsibilities.
In a company of a few hundred people those roles often sit with three or four individuals, and some sit with consultants. Write the split into the validation plan for each system. When the same requirement is visible to IT and Quality at once, disagreements about who retests what surface at the change request, not during the inspection.
How should a biotech validate its first SaaS systems?
Start from the vendor's documentation, then make it yours. Annex 11 clause 3.3 says documentation supplied with off-the-shelf products should be reviewed by regulated users to check that user requirements are fulfilled. Clause 3.1 says formal agreements with suppliers should state the supplier's responsibilities, and clause 3.2 says the need for a supplier audit should rest on a risk assessment.
In practice that means three steps. Write or adopt user requirements for how you will use the system, not every feature it has. Assess the supplier, using its quality certificates, audit reports and release process. Then test what the supplier's evidence does not cover: your configuration, your integrations and the functions that carry GMP risk.
In Matrix Validate, supplied requirements become items you review and approve for your configuration, each one scored for risk and linked to the test that verifies it. Trace rules then flag any requirement without a test before go-live, which is the gap an inspector looks for first in a system validated under deadline.
How much testing does a small CSV team really need to do?
Enough to cover the risk, and no more. Annex 11 clause 1 ties the extent of validation to a documented risk assessment, and ICH Q9(R1) says the level of effort, formality and documentation of quality risk management should be commensurate with the level of risk. FDA's Computer Software Assurance guidance of 3 February 2026 takes the same risk-based view for production and quality system software.
For a biotech, that is the difference between a CSV team of two keeping up and falling behind. A function that feeds a batch decision, an audit trail or an electronic signature earns scripted testing with evidence. A report layout or a low-impact configuration may need only a documented assessment or unscripted testing.
Matrix Validate scores each requirement or function for patient safety, product quality and data integrity impact, and every control links to the test that verifies it. The test scope then follows from scores Quality has already approved, which is easier to defend in an inspection than a judgement made under deadline. See our CSA software ranking for the tools that market CSA explicitly.
What changes between phase 1 and commercial supply?
The number of systems, the depth of the evidence and the people who will read it. In phase 1 the computer systems in scope are often few, and Part 211 does not yet apply to investigational drug production under 21 CFR 210.2(c). By phase 3 the same company is usually running an eQMS, a LIMS and an ERP, and preparing for a pre-approval inspection.
Three things tend to change. Requirements move from a vendor's brochure to approved URS items. Testing moves from vendor evidence to your own scripted tests on high-risk functions. Reporting moves from a folder of PDFs to a validation summary report per system that an inspector can follow from requirement to result.
Validation software earns its place in that transition when it lets you start light and add rigour without migrating again. That is why we rank requirements as data first: the URS you approve in phase 2 is the same item you trace, test and revalidate in commercial supply.
How do you keep up with vendor releases without a bigger team?
By making the release a query, not a project. Each change in the vendor's release notes either touches a function you rely on or it does not. The ones that do map to requirements, and those requirements map to risks and tests. Annex 11 clause 10 asks that any change, including configuration changes, be made in a controlled manner in accordance with a defined procedure.
In Matrix Validate you copy the validated project, apply the vendor's release notes, and impact analysis flags every item downstream of what changed. Redlining shows exactly what changed and what needs retesting, so you rerun only the affected scripts and sign a new summary report. Our VLMS ranking covers release handling in more depth.
Matrix One does the same for its own platform. Major releases are announced in advance with release notes and V&V reports, and Matrix Validate comes with a pre-written validation project for the platform, covering requirements, test cases, plan and report, so revalidating the tool itself is a rerun, not a rewrite.
What should a biotech test in a demo of validation software?
Run the same six checks with every vendor and keep the outputs:
Import a real URS from Word or Excel and see how it becomes items you can approve.
Score three requirements for risk and check that the test depth changes with the score.
Load a real vendor release note and ask what needs retesting.
Execute two steps, fail one, attach a screenshot and raise a deviation against the failed step.
Sign the summary report and check that the signing step asks for full credentials.
Ask for the vendor's validation package for its own tool, and how long your team needs to execute it.
The first three checks are the biotech test, because they show whether a small team can own its requirements and keep up with change. Most tools on this list handle checks four and five well.
How do you move validation out of Word and Excel?
Start with systems that are live and changing, not the archive. Packages approved in Word or PDF can stay as the historical record. What moves are the requirements and test scripts you will reuse at the next change.
Matrix Validate imports existing requirements and test scripts from Word or Excel and structures them into items, so you reuse test cases across GxP systems and rerun them at every release. Annex 11 clause 4.8 applies when data move to another format or system: validation should check they are not altered in value or meaning. Our Excel and SharePoint alternative post covers the move in more detail.
Can AI help a small biotech validation team?
Yes, if a named person approves every item it drafts. Several vendors here now market AI: ValGenesis calls itself AI-native, Res_Q describes agentic validation, and Valkit.ai says its AI proposals are never auto-applied. For a small team, the question is what the AI may change on its own.
Matrix Validate's built-in AI drafts test cases from your requirements and finds traceability gaps. A person reviews and approves every item before it is saved; nothing is approved automatically. For a biotech, gap finding often matters more than drafting, because gaps creep in when systems arrive faster than the team grows.
Where should you go next?
For the product, read the Matrix Validate overview and the computer system validation page. For the EU side, our EU GMP Annex 11 readiness page has a six-step gap assessment: inventory, owned requirements, audit trails, access control, supplier agreements and periodic review.
For the wider category, see the best validation software, the best computer system validation software, the best 21 CFR Part 11 compliant validation software and the best digital validation software.
Summary: which validation software is best for biotech companies in 2026?
Matrix Validate is the best validation software for biotech companies in 2026, because a growing biotech's validation problem is systems arriving faster than the CSV team grows, and Matrix Validate keeps every requirement, risk and test connected as data, scales testing to risk under GAMP 5 and ICH Q9(R1), and shows exactly what to retest at each SaaS release, so a small team keeps the trace matrix current from phase 2 to commercial supply. The top three:
Matrix Validate: requirements as data, risk-scaled testing and impact analysis at every release, as SaaS or on-premise.
Kneat Gx: digital validation at global scale across many validation types, trusted by 9 of the top 10 life sciences companies by Kneat's own count.
Veeva Validation Management: validation in the same Vault suite as QualityDocs and QMS, with a single audit trail.
Last updated: 9 November 2026.
Validation software for biotech companies: frequently asked questions
Under 21 CFR 210.2(c), the production of an investigational drug for a phase 1 study is exempt from Part 211, so 211.68(b) does not yet apply to that production. The exemption ends once the drug is made available for a phase 2 or phase 3 study or is marketed.
Part 11 still applies to electronic records kept under other FDA record requirements, and many biotechs start their system inventory in phase 1 so they are not validating everything at once later.
Yes. Matrix Validate is built for CSV teams validating configured, custom and SaaS systems, and it also covers simple in-house equipment qualification. Process, cleaning and analytical method validation are outside its current focus, so a team doing CSV only is the core use case, not a cut-down one.
A human is always in the loop. Matrix Validate's built-in AI drafts test cases from your requirements and finds traceability gaps, and a person reviews and approves every item before it is saved. Nothing is approved automatically.
Yes. Testers run scripts step by step with pass or fail, comments, screenshots and attachments recorded against each step as they test. Every change is recorded with who made it and when, and every e-signature asks for full credentials at the point of signing.
Review the vendor's documentation against your own user requirements, as Annex 11 clause 3.3 asks, and agree the supplier's responsibilities in writing under clause 3.1. At each release, map the release notes to the requirements they touch and retest only those. In Matrix Validate, impact analysis and redlining show which scripts to rerun.
You do, because 21 CFR 11.10(a) applies to any system holding your GxP records. Ask each vendor for its validation package. Matrix Validate comes with a pre-written validation project for the platform, covering requirements, test cases, plan and report, which your team reviews and executes.
Buy for the work you have in the next two years. If cleaning, process and facility validation across several sites dominate, the large platforms such as Kneat Gx and ValGenesis are built for that. If the work is mainly validating configured and SaaS systems, a CSV-focused tool such as Matrix Validate fits a small team better.